LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) Files An 8-K Other Events
ITEM 8.01 OTHER EVENTS.
Company) issued a press release announcing positive top-line
results from the ATHOS-3 Phase 3 Study of LJPC-501. The press
release is filed herewith as Exhibit 99.1.
its website a copy of an investor presentation regarding the
top-line results of the ATHOS-3 Phase 3 study. A copy of this
presentation is filed herewith as Exhibit 99.2.
on Form 8-K:
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Press Release dated February 27, 2017
|
|
|
99.2
|
Investor Presentation dated February 27, 2017
|
About LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC)
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products. Its product candidates in development include LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. The Company is developing LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). The Company is developing LJPC-401 for the treatment of iron overload, which occurs as a result of diseases, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. It is developing LJPC-30Sa and LJPC-30Sb not only for the treatment of serious bacterial infections but also for the potential treatment of rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) Recent Trading Information
LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) closed its last trading session down -1.61 at 33.51 with 2,248,357 shares trading hands.